MASH
Aligos Therapeutics’ HERALD Study Shows Promising MASH Treatment Results, Yet Fails to Impress Investors
Aligos Therapeutics, HERALD study, MASH treatment, ALG-055009, liver fat reduction, Phase 2a results, investor reaction.
Madrigal’s MASH Drug Rezdiffra Surpasses Q2 Sales Estimates
Madrigal Pharmaceuticals, Rezdiffra, MASH drug, Q2 earnings, sales estimates, FDA approval, commercial launch, NASH treatment
Boehringer Ingelheim and Zealand Unveil Promising Fibrosis Data from Mid-Stage MASH Trial
Boehringer Ingelheim, Zealand, fibrosis, MASH trial, mid-stage, Phase II data, liver scarring, treatment
Lilly Touts Fibrosis Win, Strengthens Case for Tirzepatide in MASH Treatment
Eli Lilly, Tirzepatide, MASH, Fibrosis, Liver Disease, Obesity, Diabetes, GLP-1/GIP Dual Agonist
Lilly’s Tirzepatide Demonstrates Efficacy in Mid-Stage MASH Study
Tirzepatide, MASH, Eli Lilly, Fibrosis, Liver Disease, Diabetes, Obesity